Big Pharma is making billions of dollars annually on TREATMENTS for multiple sclerosis that is not intended to cure patients. This is a strain on our health care costs and will not change until novel approaches are pursued by both commercial and non commercial parties that will seek an actual CURE. The government has a vested interest to fund legitimate research for the people, the economy and to be a leader in innovation
Judith Jaffe Multiple Sclerosis Center at Weill Cornell College, Presbyterian Hospital, has a director that is researching already approved FDA drugs for other conditions that may help to reverse the myelin repair damaged in the nervous system of MS patients. The director is a leading leading authority on neural regeneration and needs $2-$5m to continue studies.